EU5 · mRNA flu · 2027—2035

Five EU5 markets. One mRNA flu league table.

Five-market ranking, three scenario envelopes, five access triggers — modelled to 2035.

Modelled mRNA share of total seasonal flu volume, base case 2035. Country-level values, scenario gaps and four of five access triggers held back inside the live model — sample of MarketVIEW: Seasonal influenza vaccines (CAT VAMV036).

5
EU5 markets
modelled to 2035
3
scenarios
upside · base · conservative
5
access triggers
one revealed, four held
2×
upside-to-conservative
revenue exposure gap
Latest · Jun 2026

Read-through for EU5: Moderna’s mRNA seasonal flu vaccine mFLUSIVA (mRNA-1010) cleared the US FDA’s VRBPAC on 18 June 2026 with unanimous 9–0 votes that benefits outweigh risks in adults 50–64 and 65+, on the back of a Phase 3 (P304) showing ~27% higher relative efficacy versus a licensed standard-dose comparator. A US licensure decision is pending and an EU filing is expected to follow — bringing the first mRNA flu approval inside the EU5 window modelled here materially closer. The country rankings, scenarios and access triggers below are unchanged; this is exactly the kind of regulatory signal the model’s upside triggers are built to track. Source: Fierce Biotech →

Teaser 01 — The ranking

Five EU5 markets. One mRNA flu league table.

Modelled mRNA share of total seasonal flu volume, 2035 base case. Rank order shown. Country-level figures live inside the model.

01
Germany
—.—%
02
Spain
—.—%
03
Italy
—.—%
04
France
—.—%
05
UK
—.—%
One reveal Leader-to-laggard 2035 spread: <3× — closer than the headlines suggest.
Teaser 02 — The scenario fan

Base case is one number. The 2035 range is three.

EU5 mRNA flu share trajectory under three modelled scenarios. Scenario envelopes shown. Country attribution held back. Y-axis: % of total seasonal flu volume.

Upside
—.—%
All five access triggers fire across EU5. mRNA accelerates faster than the differentiated-flu recommendation envelope assumes.
Base
—.—%
Reference scenario for portfolio planning. Country mix in line with the live MarketVIEW assumptions.
Conservative
—.—%
Status-quo access. Triggers do not fire. mRNA remains a premium segment rather than the differentiated default.
One reveal Upside vs conservative gap can be up to 2× revenue exposure — large enough to change a launch decision.
Teaser 03 — The upside triggers

Same product. Five access systems. Five triggers.

What turns base case into upside? Each market needs a different signal. One trigger named, four held back inside the live model.

DE
STIKO
Ständige Impfkommission · standing vaccination committee · moderate +5—6% potential
Upside trigger · revealed STIKO includes mRNA inside the 65+ differentiated flu recommendation.
ES
CCAA tenders
Autonomous-community procurement · see live model
Upside trigger · redacted Trigger named in the live model — request access for full Spanish detail.
IT
Regional tenders
AIFA-aligned regional procurement · see live model
Upside trigger · redacted Italian regional dynamics modelled inside MarketVIEW.
FR
HAS
Haute Autorité de Santé · see live model
Upside trigger · redacted French recommendation pathway modelled — full trigger held back.
UK
JCVI
Joint Committee on Vaccination and Immunisation · see live model
Upside trigger · redacted UK trigger event named in the live model — request access to view.
MarketVIEW · Seasonal influenza vaccines · CAT VAMV036

Request the live model

Country-level figures, scenario envelopes and the four remaining upside triggers are inside the live MarketVIEW model. Excel forecast + executive presentation, updated for 2026.

← Back to homepage Request the model